BR112022020298A2 - Vacinas, adjuvantes e métodos para gerar uma resposta imune - Google Patents

Vacinas, adjuvantes e métodos para gerar uma resposta imune

Info

Publication number
BR112022020298A2
BR112022020298A2 BR112022020298A BR112022020298A BR112022020298A2 BR 112022020298 A2 BR112022020298 A2 BR 112022020298A2 BR 112022020298 A BR112022020298 A BR 112022020298A BR 112022020298 A BR112022020298 A BR 112022020298A BR 112022020298 A2 BR112022020298 A2 BR 112022020298A2
Authority
BR
Brazil
Prior art keywords
vaccines
methods
adjuvants
generate
immune response
Prior art date
Application number
BR112022020298A
Other languages
English (en)
Inventor
Gusovsky Fabian
Hawkins Lynn
Ishizaka Sally
Evander Anderson David
Fluckiger Anne-Catherine
Original Assignee
Eisai R&D Man Co Ltd
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Variation Biotechnologies Inc filed Critical Eisai R&D Man Co Ltd
Publication of BR112022020298A2 publication Critical patent/BR112022020298A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINAS, ADJUVANTES E MÉTODOS PARA GERAR UMA RESPOSTA IMUNE. Trata-se de vacinas que incluem antígenos de coronavírus e E6020, assim como métodos de mitigação de infecção por coronavírus administrando-se essas vacinas.
BR112022020298A 2020-04-06 2021-04-06 Vacinas, adjuvantes e métodos para gerar uma resposta imune BR112022020298A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063005908P 2020-04-06 2020-04-06
PCT/US2021/026058 WO2021207281A2 (en) 2020-04-06 2021-04-06 Vaccines, adjuvants, and methods of generating an immune response

Publications (1)

Publication Number Publication Date
BR112022020298A2 true BR112022020298A2 (pt) 2022-12-20

Family

ID=75747059

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020298A BR112022020298A2 (pt) 2020-04-06 2021-04-06 Vacinas, adjuvantes e métodos para gerar uma resposta imune

Country Status (11)

Country Link
US (1) US20230149537A1 (pt)
EP (1) EP4132577A2 (pt)
JP (1) JP2023520603A (pt)
KR (1) KR20230034936A (pt)
CN (1) CN115916254A (pt)
AU (1) AU2021252972A1 (pt)
BR (1) BR112022020298A2 (pt)
CA (1) CA3179739A1 (pt)
IL (1) IL297093A (pt)
MX (1) MX2022012527A (pt)
WO (1) WO2021207281A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022051859A1 (en) * 2020-09-11 2022-03-17 Manuel Caruso Pseudotyped retroviral particles for inducing immunity against coronavirus infections
WO2022127946A1 (es) * 2020-12-16 2022-06-23 Instituto Finlay De Vacunas Uso de composiciones vacunales basadas en el dominio de unión al receptor del virus sars-cov-2 en el desarrollo de una inmunidad protectora

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
WO2007005583A1 (en) * 2005-06-30 2007-01-11 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
US9827190B2 (en) * 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists

Also Published As

Publication number Publication date
EP4132577A2 (en) 2023-02-15
US20230149537A1 (en) 2023-05-18
IL297093A (en) 2022-12-01
CA3179739A1 (en) 2021-10-14
WO2021207281A2 (en) 2021-10-14
AU2021252972A1 (en) 2022-11-10
KR20230034936A (ko) 2023-03-10
JP2023520603A (ja) 2023-05-17
WO2021207281A3 (en) 2021-12-16
CN115916254A (zh) 2023-04-04
MX2022012527A (es) 2023-03-13

Similar Documents

Publication Publication Date Title
BR112022001185A2 (pt) Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
BR112014013276A2 (pt) vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
CL2019003805A1 (es) Composiciones inmunógenas de senecavirus a y métodos de éstas.
UY39159A (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
AR121361A1 (es) Vacuna
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112019009131A2 (pt) vacina contra o parvovírus suíno, o vírus da síndrome respiratória e reprodutiva dos suínos e métodos de produção das mesmas
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
CO2021009379A2 (es) Formulaciones y métodos de la vacuna contra el norovirus
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
BR112018008697A2 (pt) método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação.
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
BR112016012393A2 (pt) Vacina, e, uso de uma combinação de um vírus prrs atenuado vivo e um antígeno de lawsonia intracellularis inativado